Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$314.42 - $351.91 $141,489 - $158,359
-450 Reduced 5.52%
7,708 $2.71 Million
Q1 2023

May 15, 2023

SELL
$283.23 - $323.1 $191,746 - $218,738
-677 Reduced 7.66%
8,158 $2.57 Million
Q4 2022

Feb 14, 2023

SELL
$285.76 - $321.48 $40,292 - $45,328
-141 Reduced 1.57%
8,835 $2.55 Million
Q3 2022

Nov 14, 2022

SELL
$273.83 - $305.53 $69,278 - $77,299
-253 Reduced 2.74%
8,976 $2.6 Million
Q2 2022

Aug 15, 2022

BUY
$234.96 - $292.55 $232,610 - $289,624
990 Added 12.02%
9,229 $2.6 Million
Q1 2022

May 16, 2022

BUY
$221.42 - $260.97 $64,654 - $76,203
292 Added 3.67%
8,239 $2.15 Million
Q4 2021

Feb 14, 2022

BUY
$177.01 - $223.45 $110,100 - $138,985
622 Added 8.49%
7,947 $1.75 Million
Q3 2021

Nov 15, 2021

BUY
$181.39 - $202.99 $277,889 - $310,980
1,532 Added 26.45%
7,325 $1.33 Million
Q2 2021

Aug 12, 2021

SELL
$187.49 - $221.1 $118,681 - $139,956
-633 Reduced 9.85%
5,793 $1.17 Million
Q1 2021

May 14, 2021

SELL
$207.02 - $241.31 $74,734 - $87,112
-361 Reduced 5.32%
6,426 $1.38 Million
Q4 2020

Feb 16, 2021

SELL
$207.01 - $276.09 $32,500 - $43,346
-157 Reduced 2.26%
6,787 $1.6 Million
Q3 2020

Nov 13, 2020

BUY
$255.65 - $303.1 $642,192 - $761,387
2,512 Added 56.68%
6,944 $1.89 Million
Q2 2020

Aug 13, 2020

BUY
$225.48 - $295.8 $268,772 - $352,593
1,192 Added 36.79%
4,432 $1.29 Million
Q1 2020

May 14, 2020

BUY
$199.77 - $247.81 $647,254 - $802,904
3,240 New
3,240 $771,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Strategic Global Advisors, LLC Portfolio

Follow Strategic Global Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Strategic Global Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Strategic Global Advisors, LLC with notifications on news.